Bacteriophage Therapy: Advances in Formulation Strategies and Human Clinical Trials

Annual Review of Virology

Volumn 2, Issue , 2015, Pages 599-618

  Vandenheuvel, Dieter ^a   Lavigne, Rob ^a   Brüssow, Harald ^b  

^a LABORATORY OF GENE TECHNOLOGY   (Belgium)

^b NESTLÉ RESEARCH CENTER   (Switzerland)

Author keywords

Bacteriophage therapy; Biotechnology; Phage therapy clinical trial; Pharmaceutical dosage formulation; Stability

Indexed keywords

MICROSPHERE;

BACTERIOPHAGE; BACTERIOPHAGE THERAPY; BELGIUM; BURN; BURN PATIENT; CHILDHOOD DISEASE; CLINICAL TRIAL (TOPIC); COMMENSAL; CRYSTAL; DIARRHEA; DRUG FORMULATION; ESCHERICHIA COLI; EXTERNAL OTITIS; FREEZE DRYING; HUMAN; IMMUNOCOMPROMISED PATIENT; LIQUID; MICROFLORA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POWDER; PREVENTION STUDY; PRIORITY JOURNAL; PUBLIC HOSPITAL; REVIEW; RISK ASSESSMENT; SHIGELLOSIS; SOLID; SPRAY DRYING; SUSPENSION; TABLET; THERAPY; WOUND INFECTION; BIOLOGICAL THERAPY; DEVICES; GENETICS; PHYSIOLOGY; PROCEDURES; TRENDS;

BACTERIOPHAGES; BIOLOGICAL THERAPY; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS;

EID: 84969256046     PISSN: 2327056X     EISSN: 23270578     Source Type: Journal    
DOI: 10.1146/annurev-virology-100114-054915     Document Type: Review

References (111)

1. Endersen L, O'Mahony J, Hill C, Ross RP, McAuliffe O, Coffey A. 2014. Phage therapy in the food industry. Annu. Rev. Food Sci. Technol. 5:327-49
2. Brovko LY, Anany H, Griffiths MW. 2012. Bacteriophages for detection and control of bacterial pathogens in food and food-processing environment. Adv. Food Nutr. Res. 67:241-88
3. Sillankorva SM, Oliveira H, Azeredo J. 2012. Bacteriophages and their role in food safety. Int. J. Microbiol. 2012:1-13
4. Tomlinson IM. 2004. Next-generation protein drugs. Nat. Biotechnol. 22:521-22
5. Sandeep K. 2006. Bacteriophage precision drug against bacterial infections. Curr. Sci. 90:631-33
6. Bruttin A, Brussow H. 2005. Human volunteers receiving Escherichia coli phage T4 orally: A safety test of phage therapy. Antimicrob. Agents Chemother. 49:2874-78
7. Gill JJ, Hyman P. 2010. Phage choice, isolation, and preparation for phage therapy. Curr. Pharm. Biotechnol. 11:2-14
8. Ackermann HW, Tremblay D, Moineau S. 2004. Long-term bacteriophage preservation. WFCC Newsl. 38:35-40
9. Tovkach FI, Zhuminska GI, Kushkina AI. 2012. Long-term preservation of unstable bacteriophages of enterobacteria. Mikrobiol. Zhurnal 74:60-66
10. Jónczyk E, Kłak M, Miedzybrodzki R, Górski A. 2011. The influence of external factors on bacteriophages. Folia Microbiol. 56:191-200
11. Vagenende V, YapMGS,Trout BL. 2009. Mechanisms of protein stabilization and prevention of protein aggregation by glycerol. Biochemistry 48:11084-96
12. Wang W. 2000. Lyophilization and development of solid protein pharmaceuticals. Int. J. Pharm. 203:1-60
13. Ameri M, Maa YF. 2006. Spray drying of biopharmaceuticals: stability and process considerations. Drying Technol. 24:763-68
14. Crowe LM, Reid DS, Crowe JH. 1996. Is trehalose special for preserving dry biomaterials? Biophys. J. 71:2087-93
15. Merabishvili M, Vervaet C, Pirnay JP, De Vos D, Verbeken G, et al. 2013. Stability of Staphylococcus aureus phage ISP after freeze-drying (lyophilization). PLOS ONE 8:e68797
16. Vandenheuvel D, Singh A, Vandersteegen K, Klumpp J, Lavigne R, Van denMooter G. 2013. Feasibility of spray drying bacteriophages into respirable powders to combat pulmonary bacterial infections. Eur. J. Pharm. Biopharm. 84:578-82
17. Vandenheuvel D, Meeus J, Lavigne R, Van den Mooter G. 2014. Instability of bacteriophages in spraydried trehalose powders is caused by crystallization of the matrix. Int. J. Pharm. 472:202-5
18. Ma Y, Pacan JC, Wang Q, Xu Y, Huang X, et al. 2008. Microencapsulation of bacteriophage Felix O1 into chitosan-alginate microspheres for oral delivery. Appl. Environ. Microbiol. 74:4799-805
19. Golshahi L, Seed KD,Dennis JJ, Finlay WH. 2008. Toward modern inhalational bacteriophage therapy: nebulization of bacteriophages of Burkholderia cepacia complex. J. Aerosol Med. Pulm. Drug Deliv. 21:351-60
20. Semler DD, Lynch KH, Dennis JJ. 2012. The promise of bacteriophage therapy for Burkholderia cepacia complex respiratory infections. Front. Cell. Infect. Microbiol. 1:27
21. Hoe S, Semler DD, Goudie AD, Lynch KH, Matinkhoo S, et al. 2013. Respirable bacteriophages for the treatment of bacterial lung infections. J. Aerosol Med. Pulm. Drug Deliv. 26:317-35
22. Tsonos J, Oosterik LH, Tuntufye HN, Klumpp J, Butaye P, et al. 2014. A cocktail of in vitro efficient phages is not a guarantee for in vivo therapeutic results against avian colibacillosis. Vet. Microbiol. 171:470-79
23. Merabishvili M, Pirnay JP, Verbeken G, Chanishvili N, Tediashvili M, et al. 2009. Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLOS ONE 4:e4944
24. Borie C, ͆anchez ML, Navarro C, Ramírez S, Morales MA, et al. 2009. Aerosol spray treatment with bacteriophage and competitive exclusion reduces Salmonella enteritidis infection in chickens. Avian Dis. 53:250-54
25. Fortier LC, Moineau S. 2009. Phage production and maintenance of stocks, including expected stock lifetimes. In Bacteriophages: Methods and Protocols, Vol. 1: Isolation, Characterization, and Interactions, ed. MRJ Clokie, AM Kropinski, pp. 203-19. New York: Humana
26. Cooper CJ, Denyer SP, Maillard JY. 2014. Stability and purity of a bacteriophage cocktail preparation for nebulizer delivery. Lett. Appl. Microbiol. 58:118-22
27. Wright A, Hawkins CH, Änggard EE, Harper DR. 2009. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa: A preliminary report of efficacy. Clin. Otolaryngol. 34:349-57
28. Golec P, Dabrowski K, Hejnowicz MS, Gozdek A, Łós JM, et al. 2011. A reliable method for storage of tailed phages. J. Microbiol. Methods 84:486-89
29. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. 2010. Stability of protein pharmaceuticals: An update. Pharm. Res. 27:544-75
30. Schade AL, Caroline L. 1943. The preparation of a polyvalent dysentery bacteriophage in a dry and stable form. I. Preliminary investigations and general procedures. J. Bacteriol. 46:463-73
31. Zierdt CH. 1988. Stabilities of lyophilized Staphylococcus aureus typing bacteriophages. Appl. Environ. Microbiol. 54:2590
32. Zierdt CH. 1959. Preservation of staphylococcal bacteriophage by means of lyophilization. Am. J. Clin. Pathol. 31:326-31
33. ClarkWA. 1962. Comparison of several methods for preserving bacteriophages. Appl.Microbiol. 10:466-71
34. Schade AL, Caroline L. 1944. The preparation of a polyvalent dysentery bacteriophage in a dry and stable form. II. Factors affecting the stabilization of dysentery bacteriophage during lyophilization. J. Bacteriol. 48:179-90
35. Schade AL, Caroline L. 1944. The preparation of a polyvalent dysentery bacteriophage in a dry and stable form. III. Stability of the dried bacteriophage towards heat, humidity, age and acidity. J. Bacteriol. 48:243-51
36. Puapermpoonsiri U, Ford SJ, van der Walle CF. 2010. Stabilization of bacteriophage during freeze drying. Int. J. Pharm. 389:168-75
37. Alfadhel M, Puapermpoonsiri U, Ford SJ,McInnes FJ, van der Walle CF. 2011. Lyophilized inserts for nasal administration harboring bacteriophage selective for Staphylococcus aureus: in vitro evaluation. Int. J. Pharm. 416:280-87
38. Golshahi L, Lynch KH, Dennis JJ, Finlay WH. 2011. In vitro lung delivery of bacteriophages KS4-M and PdblKZ using dry powder inhalers for treatment of Burkholderia cepacia complex and Pseudomonas aeruginosa infections in cystic fibrosis. J. Appl. Microbiol. 110:106-17
39. Anany H, Chen W, Pelton R, Griffiths MW. 2011. Biocontrol of Listeria monocytogenes and Escherichia coli O157:H7 in meat by using phages immobilized on modified cellulose membranes. Appl. Environ. Microbiol. 77:6379-87
40. Markoishvili K, Tsitlanadze G, Katsarava R,Morris JGJ, Sulakvelidze A. 2002. A novel sustained-release matrix based on biodegradable poly(ester amide)s and impregnated with bacteriophages and an antibiotic shows promise in management of infected venous stasis ulcers and other poorly healing wounds. Int. J. Dermatol. 41:453-58
41. Jikia D, Chkhaidze N, Imedashvili E, Mgaloblishvili I, Tsitlanadze G, et al. 2005. The use of a novel biodegradable preparation capable of the sustained release of bacteriophages and ciprofloxacin, in the complex treatment of multidrug-resistant Staphylococcus aureus-infected radiation injuries caused by exposure to Sr90. Clin. Exp. Dermatol. 30:23-26
42. Kutter E, De Vos D, Gvasalia G, Alavidze Z, Gogokhia L, et al. 2010. Phage therapy in clinical practice: treatment of human infections. Curr. Pharm. Biotechnol. 11:69-86
43. Sulakvelidze A, Kutter E. 2004. Bacteriophage therapy in humans. In Bacteriophages: Biology and Applications, ed. E Kutter, A Sulakvelidze, pp. 381-436. Boca Raton, FL: CRC Press
44. Ohtake S, Martin RA, Yee L, Chen D, Kristensen DD, et al. 2010. Heat-stablemeasles vaccine produced by spray drying. Vaccine 28:1275-84
45. Matinkhoo S, Lynch KH, Dennis JJ, Finlay WH, Vehring R. 2011. Spray-dried respirable powders containing bacteriophages for the treatment of pulmonary infections. J. Pharm. Sci. 100:5197-205
46. Carpenter JF, Crowe JH. 1989. An infrared spectroscopic study of the interactions of carbohydrates with dried proteins. Biochemistry 28:3916-22
47. Franks F, Hatley RHM, Mathias SF. 1991. Material science and the production of shelf stable biologicals. Pharm. Technol. Int. 3:24-34
48. Alvarez-Gonzalez E, Alfadhel M, Mane P, Ford SJ, Moore BD, van der Walle CF. 2012. Bioprocessing of bacteriophages via rapid drying onto microcrystals. Biotechnol. Prog. 28:540-48
49. Puapermpoonsiri U, Spencer J, van der Walle CF. 2009. A freeze-dried formulation of bacteriophage encapsulated in biodegradable microspheres. Eur. J. Pharm. Biopharm. 72:26-33
50. O'Flaherty S, Ross RP,MeaneyW, Fitzgerald GF, Elbreki MF, Coffey A. 2005. Potential of the polyvalent anti-Staphylococcus bacteriophage K for control of antibiotic-resistant staphylococci from hospitals. Appl. Environ. Microbiol. 71:1836-42
51. Esteban PP, Alves DR, Enright MC, Bean JE, Gaudion A, et al. 2014. Enhancement of the antimicrobial properties of bacteriophage-K via stabilization using oil-in-water nano-emulsions. Biotechnol. Prog. 30:932-44
52. Veronese FM, Pasut G. 2005. PEGylation, successful approach to drug delivery. Drug Discov. Today 10:1451-58
53. Kim KP, Cha JD, Jang EH, Klumpp J, Hagens S, et al. 2008. PEGylation of bacteriophages increases blood circulation time and reduces T-helper type 1 immune response. Microb. Biotechnol. 1:247-57
54. Merril CR, Biswas B, Carlton RM, Jensen NC, Creed GJ, et al. 1996. Long-circulating bacteriophage as antibacterial agents. PNAS 93:3188-92
55. Vitiello CL, Merril CR, Adhya S. 2005. An amino acid substitution in a capsid protein enhances phage survival in mouse circulatory system more than a 1000-fold. Virus Res. 114:101-3
56. Canchaya C, Proux C, Fournous G, Bruttin A, Brussow H. 2003. Prophage genomics. Microbiol. Mol. Biol. Rev. 67:238-76
57. Brüssow H, Canchaya C, Hardt WD. 2004. Phages and the evolution of bacterial pathogens: from genomic rearrangements to lysogenic conversion. Microbiol. Mol. Biol. Rev. 68:560-602
58. Sarker SA, McCallin S, Barretto C, Berger B, Pittet AC, et al. 2012. Oral T4-like phage cocktail application to healthy adult volunteers from Bangladesh. Virology 434:222-32
59. McCallin S, Alam Sarker S, Barretto C, Sultana S, Berger B, et al. 2013. Safety analysis of a Russian phage cocktail: from metagenomic analysis to oral application in healthy human subjects. Virology 443:187-96
60. Yang J, Chen L, Sun L, Yu J, Jin Q. 2008. VFDB 2008 release: An enhanced web-based resource for comparative pathogenomics. Nucleic Acids Res. 36:D539-42
61. Liu B, Pop M. 2009. ARDB-Antibiotic Resistance Genes Database. Nucleic Acids Res. 37:D443-47
62. Muniesa M, Imamovic L, Jofre J. 2011. Bacteriophages and genetic mobilization in sewage and faecally polluted environments. Microb. Biotechnol. 4:725-34
63. Kunisaki H, Tanji Y. 2010. Intercrossing of phage genomes in a phage cocktail and stable coexistence with Escherichia coli O157:H7 in anaerobic continuous culture. Appl. Microbiol. Biotechnol. 85:1533-40
64. Santos SB, Fernandes E, Carvalho CM, Sillankorva S, Krylov VN, et al. 2010. Selection and characterization of a multivalent Salmonella phage and its production in a nonpathogenic Escherichia coli strain. Appl. Environ. Microbiol. 76:7338-42
65. Broxmeyer L, Sosnowska D, Miltner E, Chacón O, Wagner D, et al. 2002. Killing of Mycobacterium avium and Mycobacterium tuberculosis by amycobacteriophage delivered by a nonvirulent mycobacterium: A model for phage therapy of intracellular bacterial pathogens. J. Infect. Dis. 186:1155-60
66. Brüssow H. 2001. Phages of dairy bacteria. Annu. Rev. Microbiol. 55:283-303
67. Desier F, McShan WM, van Sinderen D, Ferretti JJ, Brüssow H. 2001. Comparative genomics reveals close genetic relationships between phages from dairy bacteria and pathogenic streptococci: evolutionary implications for prophage-host interactions. Virology 288:325-41
68. Oh J, Byrd AL, Deming C, Conlan S, NISC Comp. Seq. Program, et al. 2014. Biogeography and individuality shape function in the human skin metagenome. Nature 514:59-64
69. Reyes A, Haynes M, Hanson N, Angly FE, Heath AC, et al. 2010. Viruses in the faecal microbiota of monozygotic twins and their mothers. Nature 466:334-38
70. Suttle CA. 2005. Viruses in the sea. Nature 437:356-61
71. Chibani-Chennoufi S, Sidoti J, Bruttin A,Kutter E, Sarker S, BrussowH. 2004. In vitro and in vivo bacteriolytic activities of Escherichia coli phages: implications for phage therapy. Antimicrob. Agents Chemother. 48:2558-69
72. Weiss M, Denou E, Vruttin A, Serra-Moreno R, Dillmann ML, Brüssow H. 2009. In vivo replication of T4 and T7 bacteriophages in germ-free mice colonized with Escherichia coli. Virology 393:16-23
73. Chibani-Chennoufi S, Sidoti J, Bruttin A, Dillmann ML, Kutter E, et al. 2004. Isolation of Escherichia coli bacteriophages from the stool of pediatric diarrhea patients in Bangladesh. J. Bacteriol. 186:8287-94
74. Rose T, Verbeken G, De Vos D, Merabishvili M, Vaneechoute M, et al. 2014. Experimental phage therapy of burn wound infection: difficult first steps. Int. J. Burns Trauma 4:66-73
75. Verbeken G, De VosD, VaneechouteM,Merabishvili M, Zizi M, Pirnay JP. 2007. European regulatory conundrum of phage therapy. Future Microbiol. 2:485-91
76. Pirnay JP, De Vos D, Verbeken G, Merabishvili M, Chanishvili N, et al. 2011. The phage therapy paradigm: prêt-à-porter or sur-mesure? Pharm. Res. 28:934-37
77. Pirnay JP, Blasdel BG, Bretaudeau L, Buckling A, Chanishvili N, et al. 2015. Quality and safety requirements for sustainable phage therapy products. Pharm. Res. 32:2173-79
78. Pirnay JP, Verbeken G, Rose T, Jennes S, Zizi M, et al. 2012. Introducing yesterday's phage therapy in today's medicine. Future Virol. 7:379-90
79. Miedzybrodzki R, Borysowski J, Weber-Dabrowska B, Fortuna W, Letkiewicz S, et al. 2012. Clinical aspects of phage therapy. Adv. Virus Res. 83:73-121
80. ParrachoHMRT, Burrowes BH, EnrightMC, McConville ML,HarperDR. 2012. The role of regulated clinical trials in the development of bacteriophage therapeutics. J. Mol. Genet. Med. 6:279-86
81. Verbeken G, Pirnay JP, Lavigne R, Jennes S, De Vos D, et al. 2014. Call for a dedicated European legal framework for bacteriophage therapy. Arch. Immunol. Ther. Exp. 62:117-29
82. Huys I, Pirnay JP,Lavigne R, Jennes S,DeVos D, et al. 2013. Paving a regulatory pathway for phage therapy: Europe should muster the resources to financially, technically and legally support the introduction of phage therapy. EMBO Rep. 14:951-54
83. Verbeken G, Huys I, Pirnay JP, Jennes S, Chanishvili N, et al. 2014. Taking bacteriophage therapy seriously: A moral argument. Biomed. Res. Int. 2014:1-8
84. Reardon S. 2014. Phage therapy gets revitalized. Nature 510:15-16
85. Matsuzaki S, Uchiyama J, Takemura-Uchiyama I, Daibata M. 2014. Perspective: The age of the phage. Nature 509:S9
86. Fogelman I, Davey V, Ochs HD, Elashoff M, Feinberg MB, et al. 2000. Evaluation of CD4+ T cell function in vivo in HIV-infected patients as measured by bacteriophage phiX174 immunization. J. Infect. Dis. 182:435-41
87. Rubinstein A, Mizrachi Y, Bernstein L, Shliozberg J, Golodner M, et al. 2000. Progressive specific immune attrition after primary, secondary and tertiary immunizations with bacteriophage PdblX174 in asymptomatic HIV-1 infected patients. AIDS 14:F55-62
88. Ochs HD, Davis SD, Wedgewood RJ. 1971. Immunologic responses to bacteriophage PdblX 174 in immunodeficiency diseases. J. Clin. Investig. 50:2559-68
89. Rhoads DD, Wolcott RD, Kuskowski MA,Wolcott BM,Ward LS, Sulakvelidze A. 2009. Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. J. Wound Care 18:237-43
90. Grice EA, Kong HH, Renaud G, Young AC, Bouffard GG, et al. 2008. A diversity profile of the human skin microbiota. Genome Res. 18:1043-50
91. Marza JAS, Soothill JS, Boydell P, Collyns TA. 2006. Multiplication of therapeutically administered bacteriophages in Pseudomonas aeruginosa infected patients. Burns 32:644-46
92. Weber-Dabrowska B, Mulczyk M, Górski A. 2000. Bacteriophage therapy of bacterial infections: An update of our institute's experience. Arch. Immunol. Ther. Exp. 48:547-51
93. Denou E, Bruttin A, Barretto C, Ngom-Bru C, BrüssowH, Zuber S. 2009. T4 phages against Escherichia coli diarrhea: potential and problems. Virology 388:21-30
94. Zuber S, Ngom-Bru C, Barretto C, Bruttin A, Brussow H, Denou E. 2007. Genome analysis of phage JS98 defines a fourth major subgroup of T4-like phages in Escherichia coli. J. Bacteriol. 189:8206-14
95. BourdinG, Schmitt B, MavinGuy L, Germond JE, Zuber S, et al. 2014. Amplification and purification of T4-like Escherichia coli phages for phage therapy: from laboratory to pilot scale. Appl. Environ. Microbiol. 80:1469-76
96. Bourdin G, Navarro A, Sarker SA, Pittet AC, Qadri F, et al. 2014. Coverage of diarrhoea-associated Escherichia coli isolates from different origins with two types of phage cocktails. Microb. Biotechnol. 7:165-76
97. Sarker SA, Sultana S, Fuchs GJ, Alam NH, Azim T, et al. 2005. Lactobacillus paracasei strain ST11 has no effect on rotavirus but ameliorates the outcome of nonrotavirus diarrhea in children from Bangladesh. Pediatrics 116:e221-28
98. Hurley JC. 1992. Antibiotic-induced release of endotoxin: A reappraisal. Clin. Infect. Dis. 15:840-54
99. Cook GC. 1985. Infective gastroenteritis and its relationship to reduced gastric acidity. Scand. J. Gastroenterol. Suppl. 111:17-23
100. Maura D,Morello E, du Merle L, Bomme P, Le Bouguénec C, Debarbieux L. 2012. Intestinal colonization by enteroaggregative Escherichia coli supports long-term bacteriophage replication in mice. Environ. Microbiol. 14:1844-54
101. Debarbieux L. 2014. Bacterial sensing of bacteriophages in communities: The search for the Rosetta stone. Curr. Opin. Microbiol. 20:125-30
102. Reyes A, Wu M, McNulty NP, Rohwer FL, Gordon JI. 2013. Gnotobiotic mouse model of phagebacterial host dynamics in the human gut. PNAS 110:20236-41
103. Wiggins B, Alexander M. 1985. Minimum bacterial density for bacteriophage replication: implications for significance of bacteriophages in natural ecosystems. Appl. Environ. Microbiol. 49:19-23
104. Barletta F, Ochoa TJ, Mercado E, Ruiz J, Ecker L, et al. 2011. Quantitative real-time polymerase chain reaction for enteropathogenic Escherichia coli: A tool for investigation of asymptomatic versus symptomatic infections. Clin. Infect. Dis. 53:1223-29
105. Albert MJ, Farugue AS, Farugue SM, Sack RB, Mahalanabis D. 1999. Case-control study of enteropathogens associated with childhood diarrhea in Dhaka, Bangladesh. J. Clin. Microbiol. 37:3458-64
106. Brüssow H. 2013. Bacteriophage-host interaction: from splendid isolation into a messy reality. Curr. Opin. Microbiol. 16:500-6
107. Babalova EG, Katsitadze KT, Sakvarelidze LA, Imnaishvili NS, Sharashidze TG, et al. 1968. Preventive value of dried dysentery bacteriophage. Zhurnal Mikrobiol. Epidemiol. Immunol. 45:143-45 (In Russian)
108. Sulakvelidze A, Alavidze Z, Morris JG. 2001. Bacteriophage therapy. Antimicrob. Agents Chemother. 45:649-59
109. Jones JB, Vallad GE, Iriarte FB, Obradovíc A, Wernsing MH, et al. 2012. Considerations for using bacteriophages for plant disease control. Bacteriophage 2:208-14
110. Tsonos J, Vandenheuvel D, Briers Y, De Greve H, Hernalsteens JP, Lavigne R. 2014. Hurdles in bacteriophage therapy: deconstructing the parameters. Vet. Microbiol. 171:460-69
111. Johnson RP, Gyles CL, Huff WE, Ojha S, Huff GR, et al. 2008. Bacteriophages for prophylaxis and therapy in cattle, poultry and pigs. Anim. Health Res. Rev. 9:201-15